NasdaqGS:MRNABiotechs
Is Discontinuing the CMV Vaccine Changing the Investment Thesis for Moderna (MRNA)?
Earlier this month, Moderna announced it would discontinue development of its experimental cytomegalovirus (CMV) vaccine after the Phase 3 trial failed to meet primary efficacy goals, achieving just 6% to 23% effectiveness in preventing infections among seronegative women of childbearing age.
This outcome represents a considerable setback to one of Moderna's most-watched vaccine candidates and highlights the challenges of translating mRNA technology to complex viral targets beyond...